-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
With the development of innovative drugs at home and abroad in full swing, new achievements and progress continue to emer.
Recently, a number of pharmaceutical companies’ innovative drug projects have ushered in new progress, including production application, clinical approval, and initiation of clinical registrati.
Jingxin Pharmaceutical: Andacini Capsules Reported for Production On the evening of April 22, Jingxin Pharmaceutical announced that the company's new class 1 drug, Andacini capsules for the treatment of adult insomnia, was reported for producti.
The application is also the company's first small molecule innovative drug marketing application, marking a milestone in the company's innovative drug research and developme.
As of the announcement date, Jingxin Pharmaceutical has invested about 200 million yuan in research and development on the dr.
CSPC: Cisplatin Micellar Injection Approved for Clinical On the evening of April 20, CSPC announced that the cisplatin micellar injection developed by its subsidiary Zhongqi Pharmaceutical Technology (Shijiazhuang) has been approved by the State Food and Drug Administration Clinical trials can be conducted in Chi.
The clinical indications approved this time are advanced malignant solid tumo.
The product belongs to the Chinese chemical drug registration category 2, and there is currently no similar product on the market in the wor.
The results of preclinical studies show that compared with the common preparation of cisplatin, cisplatin micelle injection exists in the blood for a long time in the form of micelles after administration, which prolongs the circulation time of cisplatin in the blood; and at the same dose, The toxicity in rats and beagle dogs was significantly reduced, and the safety was significantly improv.
At the same time, it has shown good anti-tumor effects in a variety of tumor animal mode.
Hansoh Pharma: Several new drugs (new indications) have been approved for clinical use Recently, Hansoh Pharma has had several new drugs (new indications) approved for clinical use, including the company's self-developed Class 1 innovative drug HS-10386 tablets, Class 1 innovative drugs New indications for innovative drug HS-10384 tablets and Class 1 innovative drug "Pemosatide Injection", of which HS-10386 tablets are intended for the treatment of advanced solid tumors, and HS-10384 tablets are intended for menopause vasomotor therapy syndrome, and its specific indications will be determined after clinical tria.
The new indication of "pemosatide injection" is proposed for the treatment of anemia in non-dialysis chronic kidney disease patients not receiving erythropoietin therapy
Kelun Pharmaceutical: The innovative drug SKB264 was approved for clinical use In April, Kelun Pharmaceutical announced that the innovative drug SKB264 (TROP2-ADC) developed by the company's holding subsidiary Kelun Botai was combined or not combined with KL-A167 (PD- The Phase II clinical study of L1 monoclonal antibody) in the first-line treatment of patients with unresectable locally advanced, recurrent or metastatic triple-negative breast cancer (TNBC) received a clinical trial notice from the National Medical Products Administration (NMP.
Conclusion It is not difficult to see that many innovative drug companies are actively promoting project research and development recent.
From the overall background, in recent years, supported by policies, capital, talents and other aspects, the research and development of local innovative drugs is also accelerati.
However, it needs to be mentioned that there are also many challenges for innovative pharmaceutical compani.
For example, analysts at Southwest Securities once pointed out that basic research is relatively weak, and there is still room for improvement in the number of top life science and medical research institutions; The hot frontier is the main focus, and the basic research still faces many shortcomings; China's drug research and development is seriously homogeneo.
In general, these problems need to be faced by innovative drug compani.
With the accelerated research and development of innovative drugs, policies against "pseudo-innovation", and fierce competition in the market homogenization, it will be a major issue for local pharmaceutical companies to gain a firm footho.
challen.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
Recently, a number of pharmaceutical companies’ innovative drug projects have ushered in new progress, including production application, clinical approval, and initiation of clinical registrati.
Jingxin Pharmaceutical: Andacini Capsules Reported for Production On the evening of April 22, Jingxin Pharmaceutical announced that the company's new class 1 drug, Andacini capsules for the treatment of adult insomnia, was reported for producti.
The application is also the company's first small molecule innovative drug marketing application, marking a milestone in the company's innovative drug research and developme.
As of the announcement date, Jingxin Pharmaceutical has invested about 200 million yuan in research and development on the dr.
CSPC: Cisplatin Micellar Injection Approved for Clinical On the evening of April 20, CSPC announced that the cisplatin micellar injection developed by its subsidiary Zhongqi Pharmaceutical Technology (Shijiazhuang) has been approved by the State Food and Drug Administration Clinical trials can be conducted in Chi.
The clinical indications approved this time are advanced malignant solid tumo.
The product belongs to the Chinese chemical drug registration category 2, and there is currently no similar product on the market in the wor.
The results of preclinical studies show that compared with the common preparation of cisplatin, cisplatin micelle injection exists in the blood for a long time in the form of micelles after administration, which prolongs the circulation time of cisplatin in the blood; and at the same dose, The toxicity in rats and beagle dogs was significantly reduced, and the safety was significantly improv.
At the same time, it has shown good anti-tumor effects in a variety of tumor animal mode.
Hansoh Pharma: Several new drugs (new indications) have been approved for clinical use Recently, Hansoh Pharma has had several new drugs (new indications) approved for clinical use, including the company's self-developed Class 1 innovative drug HS-10386 tablets, Class 1 innovative drugs New indications for innovative drug HS-10384 tablets and Class 1 innovative drug "Pemosatide Injection", of which HS-10386 tablets are intended for the treatment of advanced solid tumors, and HS-10384 tablets are intended for menopause vasomotor therapy syndrome, and its specific indications will be determined after clinical tria.
The new indication of "pemosatide injection" is proposed for the treatment of anemia in non-dialysis chronic kidney disease patients not receiving erythropoietin therapy
Kelun Pharmaceutical: The innovative drug SKB264 was approved for clinical use In April, Kelun Pharmaceutical announced that the innovative drug SKB264 (TROP2-ADC) developed by the company's holding subsidiary Kelun Botai was combined or not combined with KL-A167 (PD- The Phase II clinical study of L1 monoclonal antibody) in the first-line treatment of patients with unresectable locally advanced, recurrent or metastatic triple-negative breast cancer (TNBC) received a clinical trial notice from the National Medical Products Administration (NMP.
Conclusion It is not difficult to see that many innovative drug companies are actively promoting project research and development recent.
From the overall background, in recent years, supported by policies, capital, talents and other aspects, the research and development of local innovative drugs is also accelerati.
However, it needs to be mentioned that there are also many challenges for innovative pharmaceutical compani.
For example, analysts at Southwest Securities once pointed out that basic research is relatively weak, and there is still room for improvement in the number of top life science and medical research institutions; The hot frontier is the main focus, and the basic research still faces many shortcomings; China's drug research and development is seriously homogeneo.
In general, these problems need to be faced by innovative drug compani.
With the accelerated research and development of innovative drugs, policies against "pseudo-innovation", and fierce competition in the market homogenization, it will be a major issue for local pharmaceutical companies to gain a firm footho.
challen.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyo.
